Immunocore (IMCR) Competitors $34.21 -1.08 (-3.06%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$34.25 +0.04 (+0.12%) As of 10/3/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, TGTX, and CRSPShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics CRISPR Therapeutics Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Does the media prefer GRFS or IMCR? In the previous week, Grifols had 3 more articles in the media than Immunocore. MarketBeat recorded 4 mentions for Grifols and 1 mentions for Immunocore. Immunocore's average media sentiment score of 1.49 beat Grifols' score of 1.04 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in GRFS or IMCR? 84.5% of Immunocore shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, GRFS or IMCR? Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.88$169.80M$1.178.50Immunocore$310.20M5.56-$51.09M-$0.40-85.53 Is GRFS or IMCR more profitable? Grifols has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Immunocore -5.70%-5.40%-1.93% Which has more risk and volatility, GRFS or IMCR? Grifols has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Do analysts recommend GRFS or IMCR? Grifols presently has a consensus target price of $10.30, indicating a potential upside of 3.52%. Immunocore has a consensus target price of $56.89, indicating a potential upside of 66.29%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50Immunocore 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryGrifols beats Immunocore on 10 of the 17 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72B$3.35B$6.12B$10.57BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-85.5322.1486.8826.70Price / Sales5.56463.17608.54240.62Price / CashN/A46.3226.3031.09Price / Book4.759.9012.536.57Net Income-$51.09M-$52.45M$3.30B$276.78M7 Day Performance0.56%5.22%4.28%2.42%1 Month Performance-8.04%10.61%6.90%8.63%1 Year Performance9.96%25.03%70.54%31.60% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore2.5533 of 5 stars$34.21-3.1%$56.89+66.3%+10.0%$1.72B$310.20M-85.53320Positive NewsGRFSGrifols3.6279 of 5 stars$9.93+1.1%$10.30+3.7%+11.5%$6.75B$7.81B8.4923,822News CoveragePositive NewsShort Interest ↑RYTMRhythm Pharmaceuticals3.5235 of 5 stars$100.64+1.5%$106.64+6.0%+99.5%$6.59B$130.13M-33.44140RNAAvidity Biosciences2.5545 of 5 stars$42.63-0.7%$68.32+60.3%-0.6%$6.27B$10.90M-11.97190Positive NewsABVXAbivax3.1076 of 5 stars$83.33+0.6%$102.14+22.6%+758.1%$6.26BN/A0.0061Analyst RevisionLEGNLegend Biotech2.8125 of 5 stars$32.85-1.6%$74.22+125.9%-34.7%$6.16B$627.24M-37.332,609CYTKCytokinetics3.872 of 5 stars$53.89+6.9%$75.71+40.5%+0.5%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2621 of 5 stars$84.84+4.2%$119.50+40.9%-19.7%$5.87BN/A-17.3140Insider TradeAXSMAxsome Therapeutics4.8326 of 5 stars$117.62+0.7%$177.86+51.2%+38.9%$5.83B$385.69M-23.20380Trending NewsAnalyst ForecastAnalyst RevisionTGTXTG Therapeutics4.3862 of 5 stars$36.83+3.7%$48.00+30.3%+65.1%$5.63B$329M99.54290CRSPCRISPR Therapeutics1.9366 of 5 stars$63.77+3.4%$71.50+12.1%+49.3%$5.61B$37.31M-11.74460News Coverage Related Companies and Tools Related Companies GRFS Competitors RYTM Competitors RNA Competitors ABVX Competitors LEGN Competitors CYTK Competitors NUVL Competitors AXSM Competitors TGTX Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMCR Stock Alerts